Abstract: The present disclosure relates to the field of biotechnology, and more specifically, to single-chain and multi-chain chimeric polypeptides having a linker domain positioned between two target-binding domains that are useful for a variety of applications including, without limitation, stimulating an immune cell, inducing or increasing proliferation of an immune cell, inducing differentiation of an immune cell, or treating a subject in need thereof (e.g., a subject having cancer or an aging-related disease or condition).
Abstract: The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.
Abstract: The present disclosure relates to methods that include the use of a first multi-chain chimeric polypeptide and a second multi-chain chimeric polypeptide for stimulating the NK cells, inducing or increasing proliferation of the NK cells, inducing differentiation of the NK cells, and treating a subject in need thereof using activated NK cells.
Abstract: The present disclosure relates to novel anti-CLEC2D antibodies and related compositions and methods of use thereof. These antibodies are used as therapeutics, and in prognostic and diagnostic applications in various cancers and other diseases.
Abstract: The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.
Type:
Grant
Filed:
January 21, 2021
Date of Patent:
November 21, 2023
Assignee:
Qu Biologics Inc.
Inventors:
Harold David Gunn, Salim Dhanji, David W. Mullins
Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.
Type:
Grant
Filed:
October 9, 2020
Date of Patent:
November 21, 2023
Assignee:
EAGLE BIOLOGICS, INC.
Inventors:
Alyssa M. Larson, Alisha K. Weight, Kevin Love, Alan Crane, Robert S. Langer, Alexander M. Klibanov
Abstract: The inventive subject matter includes an antimicrobial peptide vectored composition made of a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules. More specifically these novel recombinant antimicrobial peptide effector molecules exhibit preferential anti-microbial activity. The utility of the current inventive subject matter has demonstrated a reduced viability of Eimeira acervulina sporozoites in vitro using a sporozoite killing assay. More specifically, the antimicrobial peptide vectored composition is a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules, wherein the one or more recombinant antimicrobial peptide effector molecules are engineered from a NK-lysin gene and the one or more recombinant antimicrobial peptide effector molecules are engineered to express functionally active NK-2.
Type:
Grant
Filed:
June 14, 2021
Date of Patent:
November 14, 2023
Assignee:
US Biologic, Inc
Inventors:
Jolieke Gerdy Van Oosterwijk, Luciana Meirelles Richer, Douglas Steven Zatechka, Woohyun Kim, Hyun Soon Lillehoj, Cyril Gray, Christopher Anthony Przybyszewski
Abstract: A system for generating a model for predicting a molecular property of a variant of a molecule is provided. For each of a plurality of variants of the molecule, the system for each structural feature, aggregates the values for the structural features of the residues of the molecule that were modified to form the variant to form a feature vector for the variant. The system assigns the value for the molecular property of the variant to the feature vector wherein the feature vector and the assigned value form training data. The system then generates the model for predicting a value for the molecular property using the training data for the plurality of variants.
Type:
Grant
Filed:
June 8, 2018
Date of Patent:
October 31, 2023
Assignee:
Just-Evotec Biologics, Inc.
Inventors:
Jeremy Martin Shaver, Randal Robert Ketchem
Abstract: Provided are a cell strain HEK293.CS for reducing the production of a replication competent adenovirus, and a construction method and the use thereof. HEK293.CS is a safe adenovirus-producing cell line constructed by knocking out a gene fragment homologous to the Ad5 adenovirus E1 gene in HEK293 and providing a template plasmid to replace said gene fragment with a non-homologous sequence that stabilizes the expression of the E1 gene. Compared with the unmodified HEK293 cell strain, HEK293.CS shows no decrease in growth ability and virus production ability, but does not produce a detectable RCA. HEK293.CS can be used for the mass culture of a recombinant human type 5 adenovirus, and reducing the probability of RCA production in the manufacture process of drugs such as vaccines and antibodies.
Type:
Grant
Filed:
March 2, 2020
Date of Patent:
October 24, 2023
Assignee:
CANSINO BIOLOGICS INC.
Inventors:
Tao Zhu, Haiyan Cui, Weiwei Chen, Lei Duan, Junqiang Li, Jin Ma, Chunlin Xin, Zhongqi Shao, Xuefeng Yu, Huihua Mao
Abstract: Through the use of a universal anti-tick antigens, multiple tick-borne diseases that occur over a significant area can be targeted for eradication. The novel reservoir targeted anti-tick treatment is designed to reduce tick numbers and thereby blocking transmission of tick-borne diseases.
Type:
Grant
Filed:
January 10, 2022
Date of Patent:
October 3, 2023
Assignee:
US Biologic, Inc
Inventors:
Jolieke Gerdy van Oosterwijk, Douglas Steven Zatechka, Jr., Luciana Meirelles Richer
Abstract: Provided herein are methods and systems for bio-printing of three-dimensional organs and organoids. Also provided herein are bio-printed three-dimensional organs and organoids for use in the generation and/or the assessment of immunological products and/or immune responses. Also provided herein are methods and system for bio-printing three-dimensional matrices.
Type:
Grant
Filed:
October 30, 2019
Date of Patent:
September 26, 2023
Assignee:
PRELLIS BIOLOGICS, INC
Inventors:
Melanie P. Matheu, Kathryn J. Parkinson, Emma R. Moulton
Abstract: NEO-201 is a humanized IgG1 monoclonal antibody (mAb) that is highly reactive against the majority of tumor tissues from many different carcinomas, including colon, pancreatic, stomach, lung, breast, and uterine cancers, but the overwhelming majority of normal tissues are not recognized by this antibody. Functional assays revealed that NEO-201 is capable of mediating both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against tumor cells. Furthermore, the growth of human pancreatic xenograft tumors in vivo was largely attenuated by treatment with NEO-201 both alone and in combination with human peripheral blood mononuclear cells (PBMC) as an effector cell source for ADCC. In vivo biodistribution studies in human tumor xenograft-bearing mice revealed that NEO-201 preferentially accumulates in the tumor but not organ tissue.
Abstract: The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.
Type:
Grant
Filed:
February 5, 2021
Date of Patent:
September 26, 2023
Assignee:
Interface Biologics, Inc.
Inventors:
Sanjoy Mullick, Weilun Chang, Hanje Chen, Mark A. Steedman, Roseita Esfand
Abstract: Anti-CD3 antibodies for use in the diagnosis or treatment of hyperproliferative or autoimmune disorders methods of using the same for detecting and/or treating a hyperproliferative or autoimmune disorders.
Type:
Application
Filed:
March 20, 2023
Publication date:
September 21, 2023
Applicant:
AbCellera Biologics Inc.
Inventors:
Lindsay DEVORKIN, Aaron Paul YAMNIUK, Bryan Crawford BARNHART, Wei WEI, Kevin HEYRIES, Harveer DHUPAR, Sherie DUNCAN, Timothy M. JACOBS
Abstract: Methods for alleviating symptoms in a Fragile X Syndrome (FXS) patient using adeno-associated viral (AAV) 9 viral particles encoding a wild-type human fragile X mental retardation 1 (FMR1) protein (human FMRP). Also provided herein are methods to determine suitable doses of AAV9 viral particles for a FXS patient to alleviate at least one symptom associated with FXS, as well as methods for monitoring treatment efficacy.
Type:
Application
Filed:
July 16, 2021
Publication date:
September 21, 2023
Applicants:
CHILDREN'S HOSPITAL MEDICAL CENTER, FORGE BIOLOGICS, INC.
Inventors:
Ernest PEDAPATI, Christina GROSS, Craig ERICKSON, David DISMUKE, Erandi Kanchana DE SILVA
Abstract: Provided herein are multi-chain chimeric polypeptides that include: (a) a first chimeric polypeptide including a first target-binding domain, a soluble tissue factor domain, and a first domain of a pair of affinity domains; and (b) a second chimeric polypeptide including a second domain of a pair of affinity domains and a second target-binding domain, where the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains. Also provided here are methods of using these multi-chain chimeric polypeptides and nucleic acids encoding these multi-chain chimeric polypeptides.
Abstract: The inventive subject matter includes an antimicrobial peptide vectored composition made of a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules. More specifically these novel recombinant antimicrobial peptide effector molecules exhibit preferential anti¬microbial activity. The utility of the current inventive subject matter has demonstrated a reduced viability of Eimeira acervulina sporozoites in vitro using a sporozoite killing assay. More specifically, the antimicrobial peptide vectored composition is a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules, wherein the one or more recombinant antimicrobial peptide effector molecules are engineered from a NK-lysin gene and the one or more recombinant antimicrobial peptide effector molecules are engineered to express functionally active NK-2.
Type:
Application
Filed:
June 14, 2021
Publication date:
August 31, 2023
Applicants:
US Biologic, Inc., The United States of America as represented by the Secretary of Agriculture
Inventors:
Jolieke Gerdy van Oosterwijk, Luciana Meirelles Richer, Douglas Steven Zatechka, Woohyun Kim, Hyun Soon Lillehoj, Cyril Gray, Christopher Anthony Przybyszewski
Abstract: The present disclosure relates to methods that include the use of a first multi-chain chimeric polypeptide and a second multi-chain chimeric polypeptide for stimulating the NK cells, inducing or increasing proliferation of the NK cells, inducing differentiation of the NK cells, and treating a subject in need thereof using activated NK cells.